AstraZeneca

News

AZ, Daiichi Sankyo cue up TROP2 drug filing in breast cancer

Armed with the first phase 3 data for their TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan as a second-line treatment for breast cancer, AstraZeneca

R&D

Partner Content

3rd ADC Target Selection Summit

Optimizing Target Selection Rationale for ADCs & Novel Format Conjugates

Home

2023 PM Society Digital Awards, OPEN Health takes 3 Golds

Over the course of 14 years, the PM Society Digital Awards have cemented their place as a highlight on the healthcare marketing calendar.

Sales & Marketing

12 Questions with Stefan Woxström

Stefan Woxström leads the Europe and Canada business at AstraZeneca and brings a wealth of experience from 27 years with the organisation, having held a variety of local and regional roles

News

WCLC: Chemo adds efficacy and side effects to AZ's Tagrisso

Giving AstraZeneca's EGFR tyrosine kinase inhibitor (TKI) inhibitor Tagrisso in combination with chemotherapy to patients with EGFR-mutated non-small cell lung cancer (NSC

News

AZ's Alexion inks wide-ranging AI agreement with Verge

AstraZeneca has made a sizeable play in applying artificial intelligence to drug discovery in its rare disease unit Alexion, partnering with Verge Genomics in a deal that

AZ, Daiichi Sankyo cue up TROP2 drug filing in breast cancer

3rd ADC Target Selection Summit

2023 PM Society Digital Awards, OPEN Health takes 3 Golds

12 Questions with Stefan Woxström

WCLC: Chemo adds efficacy and side effects to AZ's Tagrisso

AZ's Alexion inks wide-ranging AI agreement with Verge

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

AstraZeneca

Editor's Picks